The article you requested is
Drs. Puzantian and Shaw Reply
J Clin Psychiatry 1997;58:365 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
- Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: Dr. Yong’s comments regarding our letter raise the interesting
issue of the potential for an interaction between nefazodone
and risperidone via inhibition of the cytochrome P450
2D6 isoenzyme, leading to increased levels of risperidone.
Interaction studies of nefazodone with the triazolobenzodiazepines
triazolam and alprazolam, both metabolized by cytochrome
P450 3A4, have revealed substantial and clinically
significant increases in plasma triazolobenzodiazepine concentrations.
Only the benzodiazepines metabolized by the 3A4
isoenzyme have a potential interaction with nefazodone.2,3